tbuckley/cabot-search huggingface dataset:
Observations on the Cytology and Electron Microscopy of Hepatic Cells&lt;xref ref-type="fn" rid="fn1"&gt;1&lt;/xref&gt;, &lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: D W FAWCETT
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Observations on the Cytology and Electron Microscopy of Hepatic Cells, Get access Don W. Fawcett Don W. Fawcett Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue Supplement_5, April 1955, Pages 1475–1503, https://doi.org/10.1093/jnci/15.Supplement_5.1475 Published: 01 April 1955
ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC)
Authors: J. Crawford, A. B. Sandler, L. A. Hammond, J. Schiller, C. Belani, M. Kozloff, D. Johnson, A. Fleishman, S. Lee, K. Takeshita
Journal: Journal of Clinical Oncology (2004)

7083 Background: ABX-EGF is a high-affinity, fully human, IgG2 monoclonal antibody directed against epidermal growth factor receptor (EGFr). This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC. Methods: In this open-label, sequential, dose-escalation design in pts with NSCLC (stage IIIb or IV) and EGFr expression of 2+ or 3+ in >=10% of tumor cells, pts received weekly IV ABX-EGF in combination with standard paclitaxel and carboplatin every 3 weeks for up to 6 cycles; pts with response or stable disease could receive extended ABX-EGF therapy. Responses (RECIST) were evaluated at week 6 with confirmation >=3 weeks later. The PK of ABX-EGF and paclitaxel were evaluated at weeks 0 and 3. Results: Nineteen pts (5 men/14 women; mean [SD] age 52.2 [11.9] years) were enrolled into 3 ABX-EGF cohorts: 1.0 mg/kg (n=6), 2.0 mg/kg (n=7), and 2.5 mg/kg (n=6). One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment. The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups). The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg). Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities. The PK of ABX-EGF appeared to be dose dependent. PK results for paclitaxel were similar to that reported in the literature. Conclusions: ABX-EGF is well tolerated in combination with paclitaxel and carboplatin for advanced NSCLC. Part 2 of the study continues to accrue patients to further assess clinical activity in this setting. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Inc. Amgen Amgen Amgen Amgen
Seasonal and mood independence of low basal prolactin secretion in premenopausal women with seasonal affective disorder
Authors: R A Depue, P Arbisi, M R Spoont, S Krauss, A Leon, B Ainsworth
Journal: American Journal of Psychiatry (1989)

To test hypotheses of opposing roles of dopamine and serotonin in prolactin secretion in seasonal affective disorder, the authors determined basal serum prolactin concentrations for premenopausal women, eight with and 14 without seasonal affective disorder, in late afternoon during the follicular phase of the menstrual cycle (and a subgroup during the luteal phase) in winter and summer. Despite their significantly higher Hamilton depression scale scores in winter than in summer, the patients had significantly lower prolactin concentrations than the control subjects in both seasons. These results suggest that low prolactin secretion may be a trait characteristic in seasonal affective disorder.
Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis
Authors: Puya Gharahkhani, Rebecca C Fitzgerald, Thomas L Vaughan, Claire Palles, Ines Gockel, Ian Tomlinson, Matthew F Buas, Andrea May, Christian Gerges, Mario Anders, Jessica Becker, Nicole Kreuser, Tania Noder, Marino Venerito, Lothar Veits, Thomas Schmidt, Hendrik Manner, Claudia Schmidt, Timo Hess, Anne C Böhmer, Jakob R Izbicki, Arnulf H Hölscher, Hauke Lang, Dietmar Lorenz, Brigitte Schumacher, Andreas Hackelsberger, Rupert Mayershofer, Oliver Pech, Yogesh Vashist, Katja Ott, Michael Vieth, Josef Weismüller, Markus M Nöthen, Stephen Attwood, Hugh Barr, Laura Chegwidden, John de Caestecker, Rebecca Harrison, Sharon B Love, David MacDonald, Paul Moayyedi, Hans Prenen, R G Peter Watson, Prasad G Iyer, Lesley A Anderson, Leslie Bernstein, Wong-Ho Chow, Laura J Hardie, Jesper Lagergren, Geoffrey Liu, Harvey A Risch, Anna H Wu, Weimin Ye, Nigel C Bird, Nicholas J Shaheen, Marilie D Gammon, Douglas A Corley, Carlos Caldas, Susanne Moebus, Michael Knapp, Wilbert H M Peters, Horst Neuhaus, Thomas Rösch, Christian Ell, Stuart MacGregor, Paul Pharoah, David C Whiteman, Janusz Jankowski, Johannes Schumacher
Journal: The Lancet Oncology (2016)

Oesophageal adenocarcinoma represents one of the fastest rising cancers in high-income countries. Barrett's oesophagus is the premalignant precursor of oesophageal adenocarcinoma. However, only a few patients with Barrett's oesophagus develop adenocarcinoma, which complicates clinical management in the absence of valid predictors. Within an international consortium investigating the genetics of Barrett's oesophagus and oesophageal adenocarcinoma, we aimed to identify novel genetic risk variants for the development of Barrett's oesophagus and oesophageal adenocarcinoma.
The Carcinogenic Nitrogen Heterocyclics in Cigarette-Smoke Condensate&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Benjamin L. van Duuren, J. A. Bilbao, C. A. Joseph
Journal: JNCI Journal of the National Cancer Institute (1960)

The identification of 3 nitrogen heterocyclic carcinogens in cigarette tar is described. These compounds, 7H-dibenzo[c,g]carbazole, dibenz[a,j]acridine, and dibenz[a,h]acridine, were present in cigarette tar in concentrations of 0.07γ, 0.27γ, and 0.01γ per 100 cigarettes, respectively. The compounds were identified by their spectra and RF values on paper chromatograms. It was also shown that dibenz[a,j]-acridine and dibenz[a,h]acridine were formed in the pyrolysis of nicotine and of pyridine at 750° C.
PTU-189 Research design implications from a survey and focus group of ibs sufferers at a specialised patient conference
Authors: KJ Etherson, JM Mason, C Emmett, Y Yiannakou
Journal: Gut (2015)

<h3>Introduction</h3> A large patient conference attended by &gt;150 patients with irritable bowel syndrome (IBS) was hosted by County Durham and Darlington NHS Foundation Trust in July 2014. The aims were to educate, support and gain patients’ perspectives into their condition. A 45-minute session on “engaging with research” described current research and thinking into IBS, and then offered participants the opportunity to complete a survey and focus group discussion on the topic. This session was repeated three times during the conference. <h3>Method</h3> Each of the 3 sessions followed a prescribed format. A survey sheet asked participants to complete 5 multiple choice questions on health research in IBS. The cohort were then split into two focus groups led separately by a professor and specialist in health research design (JM) or a research fellow who treats and recruits patients with IBS into clinical studies (KE). Survey data was analysed quantitatively after the conference. Qualitative data was shared between researchers after each session and emerging themes explored further in the subsequent focus groups for validation. <h3>Results</h3> 78 people attended and participated over 3 sessions. Response rates varied between survey items. Patients felt that research priorities should be; investigating the causes of IBS (54%), new drug treatments (20%), and developing diagnostic tests (18%). As research participants, 85% felt it was acceptable to keep a bowel diary for ≥4 weeks and 63% felt ≥5 visits in a 6 month period during a clinical trial were acceptable. Motivations to participate in clinical trials were due to; a new treatment for IBS (65%), altruism (37%) and other factors (11%). 68% were willing to participate in studies where they might receive a placebo or sham treatment as part of the study design. Themes emerging from the focus groups emphasised the need to research the causes of IBS, particularly as a diagnosis was felt to validate their experiences and brought a sense of gaining control. The treatment of pain was felt to be “a first priority”, as was a wish for a side-effect free “magic pill”, but expectations of these were realistic. Most agreed that their IBS symptoms were highly variable and so longer diary exercises were acceptable and required. <h3>Conclusion</h3> Methodologists and clinicians involved in the design of clinical trials of investigational medicinal products for IBS should consider our patients’ ideas and their acceptability. In particular: lengthening symptom diaries, monitoring pain as a priority symptom, and frequent monthly study visits. Recruitment is not hindered by placebo or sham treatment arm designs and most patients are motivated to participate by receiving a new treatment over altruism or honorariums. <h3>Disclosure of interest</h3> None Declared.
Patient privacy and confidentiality at mental health centers
Authors: J O Noll, M J Hanlon
Journal: American Journal of Psychiatry (1976)

The authors studied potential violations by mental health centers of individuals' rights to privacy and confidentiality by sending questionnaires to state directors of mental health programs and to mental health centers in all the 50 United States and its teritories. The questionnaires assessed the extent to which information that could identify a patient is reported to state offices; it also addressed issues of mental health center discretion in reporting information, the life span of patient files, and the access of outside agencies to mental health center files. The authors conclude that legislative action prohibiting the reporting of identifying information appears desirable.
Topical Antitumoral Effects of Cortisol, as Demonstrated by the “Double Granuloma-Pouch” Technique&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Hans Selye
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Topical Antitumoral Effects of Cortisol, as Demonstrated by the “Double Granuloma-Pouch” Technique Get access Hans Selye Hans Selye Institut de Médecine et de Chirurgle expérimentales, Université de Montréal, Montreal, Canada Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 3, March 1958, Pages 581–589, https://doi.org/10.1093/jnci/20.3.581 Published: 01 March 1958 Article history Received: 16 September 1957 Published: 01 March 1958
A profile of ACT recipients in New York State during 1972 and 1977
Authors: J P Morrissey, H J Steadman, N M Burton
Journal: American Journal of Psychiatry (1981)

The authors report data on the social and clinical characteristics of patients who received ECT in public or private psychiatric facilities in New York State during 1972 and 1977. The findings indicate that the predominant use of ECT is in the private psychiatric sector and that, in both private and public facilities, it is administered primarily to white, middle-aged women with depressive conditions.
Polysomnographic studies of unmedicated depressed men before and after cognitive behavioral therapy
Authors: M E Thase, C F Reynolds, E Frank, J R Jennings, E Nofzinger, A L Fasiczka, G Garamoni, D J Kupfer
Journal: American Journal of Psychiatry (1994)

Differentiation of stable, trait-like characteristics from more episodic or state-dependent disturbances will be helpful in gaining a better understanding of the pathophysiology of depression. However, research in this area has been complicated by artifactual and clinical problems associated with pharmacologic treatment. In this investigation the authors used EEG sleep studies to assess medication-free depressed male patients before and after cognitive behavioral therapy.Forty-five male patients with the diagnosis of major depression according to the DSM-III-R criteria and the Research Diagnostic Criteria underwent EEG sleep studies before and after 16 weeks of cognitive behavioral therapy, during which they were free of medication. In addition to the documentation of changes within these patients, the findings were compared with those for 47 healthy subjects, including 15 who were restudied 12-24 months after their baseline assessments.The EEG sleep profiles of the depressed patients showed a significant reduction in REM sleep density after treatment, suggesting "normalization" of an abnormal state-dependent process. By contrast, slow wave sleep and tonic REM measures, including reduced REM latency, were unchanged after treatment.These findings suggest that early in remission there is disaggregation of irreversible, trait-like correlates of depression (e.g., diminished slow wave sleep and reduced REM latency) from more reversible disturbances (e.g., increased REM density).
Diagnostic factors in intermediate and high-grade lymphomas: pathologic, immunologic, and clinical.
Authors: P A Bunn
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.7.1073 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2899139 Diagnostic factors in intermediate and high-grade lymphomas: pathologic, immunologic, and clinical. P A Bunn JrxP A Bunn JrSearch for articles by this author Show More University of Colorado Health Science Center, Denver. https://doi.org/10.1200/JCO.1988.6.7.1073 First Page PDF © 1988 by American Society of Clinical Oncology
Carbonic Anhydrase Content of Normal and Neoplastic Tissues
Authors: B SHACTER, M B SHIMKIN
Journal: JNCI Journal of the National Cancer Institute (1948)

Journal Article Carbonic Anhydrase Content of Normal and Neoplastic Tissues Get access Bernard Shacter, Bernard Shacter Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin Laboratory of Experimental Oncology, National Cancer Institute, Public Health Service, and the University of California Medical School, San Francisco Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 3, December 1948, Pages 155–158, https://doi.org/10.1093/jnci/9.3.155 Published: 01 December 1948 Article history Received: 11 May 1948 Published: 01 December 1948
PWE-177 The functional relevance of toll-like receptor 4 mutations in oesophageal adenocarcinoma
Authors: DR Fels Elliott, B Verstak, X Li, MF Symmons, NJ Gay, RC Fitzgerald
Journal: Gut (2015)

<h3>Introduction</h3> Altered innate immune signalling may disrupt host-microbe homeostasis and promote an inflammatory microenvironment that favours tumourigenesis. The aim of this project was to assess whether somatic mutations in oesophageal adenocarcinoma (OAC) could interfere with Toll-like receptor (TLR) signalling, with a specific focus on TLR4. <h3>Method</h3> We interrogated the mutational profiles of TLR genes in 170 OAC samples, which had undergone whole genome sequencing as part of the oesophageal ICGC study. We performed site-directed mutagenesis and created 13 plasmids expressing mutant TLR4 with a CMV promoter (12 single nucleotide variants (SNVs), and one plasmid combined two SNVs). Luciferase reporter gene assays were performed in HEK293 cells stimulated with synthetic monophosphoryl lipid A (MPLA) to assess how the mutants altered TLR4 signalling and downstream activation of nuclear factor kappa B (NF-κB). Two of the TLR4 mutants were taken forward for transfection into the OAC cell line OE33, and ELISA was used to measure cytokine secretion after stimulation with MPLA. <h3>Results</h3> The TLR signalling pathway appeared to be recurrently mutated with missense mutations in 23/170 (13.5%) of tumour samples, including mutations in TLR1 (1.2%), TLR2 (0.6%), TLR4 (4.7%), TLR5 (0.6%), TLR7 (1.8%), TLR9 (1.2%), and MYD88 (1.5%). Based on our data and another recent study by Dulak <i><i>et al</i>.<sup>1</sup>,</i>TLR4 mutations were the most frequent (5.4% combined data). One tumour sample contained two TLR4 mutations, E439G and F703C. Interestingly, the mutation E439G was identified both in our dataset and in the study by Dulak <i><i>et al</i>. </i>Furthermore,<i><i>in silico</i></i>modelling suggested that the E439G mutation disrupts hydrogen bonds in the binding site of LPS and MD2. The use of NF-κB luciferase reporter assays demonstrated a significant decrease in ligand-dependent signalling for 8/12 of the TLR4 mutations tested in HEK293 cells. A double mutation of E439G with F703C revealed a further decrease in TLR4 signalling. Similarly, the concentration of IL-8 was lower for TLR4 mutants E439G and E439G+F703C transfected into OE33 cells stimulated with MPLA, in comparison to wild-type TLR4. <h3>Conclusion</h3> TLR4 is recurrently mutated in OAC, and the majority of these mutations showed decreased TLR4 signalling in response to ligand stimulation, both in HEK293 and OE33 cells. The biological relevance of this in relation to host-microbe homeostasis and carcinogenesis is being explored. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Dulak AM, <i>et al</i>. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. <i>Nat Genet. </i>2013;45(5):478–486.
Female Donors Are Associated with an Increased Risk of Chronic Graft-Versus-Host Disease (cGVHD) Independent of Recipient Sex but Provide Superior Graft-Versus-Leukemia Activity Once cGVHD Is Established
Authors: Nicola Lehners, Mark-Alexander Schwarzbich, Katharina Schmidt, Joe Puthenparambil, Aleksandar Radujkovic, Sascha Dietrich, Anthony D Ho, Peter Dreger, Thomas Luft
Journal: Blood (2014)
SAT0583 Performance of Different Inflammatory Back Pain Criteria in Psoriatic Arthritis with Chronic Low Back Pain: Table 1.
Authors: U. Kalyoncu, B. Yılmazer, Ö. Bayındır, K. Aksu, E. Dalkılıç, M.F. Öksüz, E.F. Tarhan, M. Can, O. Küçükşahin, G. Kimyon, L. Akyol, A.M. Onat, B. Kısacık, A. Erden, A. Omma, E.D. Ersözlü Bozkırlı, C. Özişler, E. Gönüllü, S. Masatlıoğlu Pehlevan, D. Solmaz, M. Çınar, G. Yıldırım Çetin, A. Tufan, M. Aydın Tufan, L. Kılıç, S. Erten, T. Kaşifoğlu, S. Kobak, S. Şenel, S. Akar, S. Yılmaz, E. Kasapoğlu Günal, M. Sayarlıoğlu, Y. Kabasakal, S.Z. Aydın
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Currently 3 sets of criteria are available for inflammatory back pain (IBP) in spondyloarthritis: Calin, Berlin and the ASAS criteria. The performances of these criterias in differentiating IBP in psoriatic arthritis (PsA) with chronic low back pain (CLBP) is currently not known. <h3>Objectives</h3> The objective of this study was to assess performance of those 3 different criteria in a large multicentre PsA cohort. <h3>Methods</h3> PsART (Psoriatic Arthritis Registry of Turkey) is a prospective, multicentre, nationwide study in Turkey on patients with PsA. Patients are consecutively recruited to this registry, if they are diagnosed as PsA, regardless of any other disease characteristics. In this registry, CLBP was defined as back pain lasting for more than 3 months. All relevant data for IBP according to Calin, Berlin and ASAS criteria for IBP were collected. <h3>Results</h3> PsARTcohort included 746 PsA (35.3% male) patients. Overall, 170 of 746 (22.9%) of patients had CLBP. Median PsA duration was 47 (0-538) months. Patients with CLBP were more frequently males (44.4% vs 32.5%, p=0.004), more frequently had pitting (54.5% vs 41.3%, p=0.014) and less frequently had polyarthritis (26.3% vs 51.3%, p&lt;0.001), and DIP joint involvement (7.0% vs 13.0%, p=0.031) than without CLBP. Patients with CLBP also had lower swollen joint counts (mean (SD):1.2 (2.5) vs 1.9 (3.0), p=0.015) and higher BASDAI values (4.6 (5.6) vs 3.5 (2.4), p=0.004). The positivity of each criteria for IBP was comparable for Berlin (n=147; 86.0%) and Calin criteria (n=148; 86.5%) and was lower with the ASAS criteria (n=114; 66.7%). The agreement rate of the Berlin and Calin criteria was 88.8% whereas this was lower between ASAS and Berlin (73.5%) as well as ASAS and Calin criteria (76.5%). When divided according to gender, the agreement of ASAS criteria vs Berlin and Calin criteria was lower only in females (ASAS vs Berlin: 61.7%; ASAS ve Calin: 71.3%, Calin vs Berlin 88.3%), whereas they performed equally in males (ASAS vs Berlin: 88.2%; ASAS ve Calin: 82.9%, Calin vs Berlin 89.5%) (Table 1). <h3>Conclusions</h3> Both Calin and Berlin criteria seem to be effective questionaires for evaluating IBP in PsA patients with CLBP. However, ASAS criteria did not perform well particularly in female patients. For this reason, the gender distribution may be an important aspect to consider when recruting patients in clinical trials as well as guiding physicians in clinical practice. <h3>Disclosure of Interest</h3> None declared
만성 B형 간염 및 간경변증 환자에서 간 섬유화의 지표로서 혈청 히아루론산과 IV형 콜라겐 7S Domain 및 AST/ALT비 등의 진단적 유용성
Authors: 박진형 ( Jin Hyung Park ), 박창근 ( Chang Kun Park ), 김은수 ( Eun Soo Kim ), 박수영 ( Soo Young Park ), 조창민 ( Chang Min Jo ), 탁원영 ( Won Young Tak ), 권영오 ( Young Oh Kweon ), 김성국 ( Sung Kook Kim ), 최용환 ( Yong Whan Choi )
Journal: Clinical and Molecular Hepatology (2003)

목적: 만성 간 질환을 가진 환자의 경과와 예후는 간 조직의 세포괴사와 염증 및 섬유화 등의 조직학적 활성도에 달려 있다고 할 수 있다. 간 조직검사는 만성 간 질환을 가진 환자에서 조직학적 활성도를 객관적으로 평가하는데 가장 중요한 검사이지만, 침습적인 방법으로 검사와 연관된 합병증의 발생 가능성이 있고, 충분한 조직 채취가 이루어지지 않을 때는 간 실질 전체를 대표하지 못할 수 있다. 최근 혈청 히아루론산과 7S 콜라겐의 농도 및 AST/ALT비 등은 만성 간 질환을 가진 환자에서 간 조직 섬유화의 진행과 밀접한 연관성이 있으며, 간경변증을 예측하는데 임상적으로 유용한 혈청학적 표지자가 될 수 있다고 보고되어 있으므로 본 연구에서는 만성 B형 간염 및 간경변증 환자들을 대상으로 간 조직 섬유화의 혈청학적 표지자로서 혈청 히아루론산과 7S 콜라겐의 농도 및 AST/ALT비 등의 진단적 유용성에 대하여 알아보고자 하였다. 대상과 방법: 만성 B형 간염 및 간경변증 환자 100명을 대상으로 하였으며, 비 대상성 간경변증 환자 10예를 제외한 총 90예의 환자에서 초음파유도하에 경피적 간 조직검사를 시행하였다. 환자들은 간 조직검사와 동시에 혈액을 채취하여 혈청 히아루론산(정상치: 50 ng/mL 이하)과 7S 콜라겐(정상치: 5 ng/mL 이하) 및 AST/ALT비 등을 측정하였으며 조직소견과의 관계를 분석하였다. 결과: 대상 환자들 중 남자는 77예, 여자는 23예이었고 평균 연령은 31±12세였다. 각 군간의 비교에서 병변이 진행할수록 혈청 AST 및 ALT의 농도는 유의성이 없었으나, 알부민 및 혈소판의 수치는 유의하게 감소하였다(p<0.05). 각 군에서 혈청 히아루론산과 7S 콜라겐의 농도 및 AST/ALT비는 정상 및 지방간군(20.2±2.5 ng/mL, 3.5±0.5 ng/mL, 0.7±0.3), 경도의 만성 간염군 (32.3±52.7 ng/mL, 3.9±1.4 ng/mL, 0.7±0.4), 중등도 이상의 만성 간염군 (68.2±72.3 ng/mL, 5.3±2.4 ng/mL, 0.8±0.4)보다 대상성 간경변군 (139.8±98.4ng/ mL, 6.9±3.5 ng/mL, 1.6±1.5)에서 유의하게 높았으며(p<0.05), 또한 비 대상성 간경변군 (1084.2±1600.6 ng/mL, 13.0±4.5 ng/mL, 3.0±1.7)에서 대상성 간경변군 보다 유의하게 높았다(p<0.01). 간 조직의 섬유화 등급에 따른 비교에서 섬유화가 없거나 초기 및 중등도 이상인군(섬유화 등급: 0-3점)보다 섬유화가 진행되어 간경변증으로 이행된군(섬유화 등급: 4점)에서 각 표지자들의 수치가 유의하게 높았다(p<0.05). 그러나 소엽내 활성과 문맥 주변부 활성에 따라 등급화한 각 군간의 비교에서는 유의한 차이를 보이지 않았다. 간 조직의 섬유화 등급 4점의 간경변증군과 섬유화 등급 0점에서 3점의 만성 간염군을 구분하는데 따른 진단적 유용성을 알아보았으며, 혈청 히아루론산과 7S 콜라겐의 농도 및 AST/ALT비 등의 cut-off 값을 각각 77 ng/mL, 6.3 ng/mL, 0.62로 설정하여 민감도와 특이도 및 진단효율을 구하였을 때, 히아루론산의 경우 민감도 81.8%, 특이도 87.3%, 진단효율 86.7%이었고, 7S 콜라겐의 경우 민감도 63.6%, 특이도 88.6%, 진단효율 85.6%이었으며 AST/ALT비의 경우 민감도 90.9%, 특이도 53.1%, 진단효율 57.8%이었다. 결론: 만성 B형 간염 바이러스성 간 질환에서 간 섬유화의 혈청학적 표지자로서 혈청 히아루론산과 7S 콜라겐의 농도 및 AST/ALT비 등은 임상적으로 유용하게 사용될 수 있을 것으로 생각된다.